透過您的圖書館登入
IP:3.144.18.4
  • 期刊

子宮頸癌高劑量率與低劑量率體腔內近接治療之現況與比較

Current Status and Comparison of High-dose-rate (HDR) Vs. Low-Dose-Rate (LDR) Intracavitary Brachytherapy in Treatment of Cervical Carcinoma

摘要


子宮頸癌體腔內近接治療的技術與趨勢,在過去的十年有極顯著的轉變:高劑量率(HDR)技術正逐漸的取代過去使用近半世紀的低劑量率(LDR)技術。臨床的報告顯示,HDR的結果與LDR相當、或比LDR略好,更重要的是嚴重的併發症有明顯的減少,這其中必須歸因於HDR射源的改進與電子機械設備的現代化,以及HDR適當的分次治療,HDR與LDR的隨機比較、最適當分次原則、直腸併發症的減少是HDR將來重要的議題。

並列摘要


Over the past one decade, there was a significant reverse in clinical attitude to the high-dose-rate (HDR) intracavitary brachytherapy for treatment of cervical carcinoma. Cumulative data from both meta-analysis and a few available randomized studies have shown that results of HDR were comparable with, or slightly superior to, that of the existing low-dose-rate (LDR) results. The improvement of treatment results, parallel with a significant reduction of severe rectal complication rate (Grade 3 and 4), has been attributed mainly to the improved physical/mechanical characteristics of HDR facility and the use of appropriately fractionated treatment. Prospective randominzed comparison of HDR vs. LDR, optimal dose-fractionation study, and prediction/prevention of rectal complication are the three central issues of HDR in the future.

延伸閱讀